Brazilian Reality of Hepatocellular Carcinoma

Launched by ASTRAZENECA · Jan 19, 2024

Keywords

ClinConnect Summary

The clinical trial titled "Brazilian Reality of Hepatocellular Carcinoma" is studying liver cancer, specifically a type called hepatocellular carcinoma. Researchers want to understand how common this cancer is, how it is treated, how it progresses, and how long patients live after being diagnosed. They are looking at data from patients treated at specialized cancer care centers across Brazil over the past six years, from 2017 to 2022.

To participate in this trial, you need to be at least 18 years old and have a confirmed diagnosis of hepatocellular carcinoma, which can be shown through a biopsy or medical imaging. The trial is open to everyone, regardless of gender. However, if you have other specific types of liver tumors or have only visited a participating healthcare center once without follow-up, you would not be eligible to join. If you qualify, you can expect to provide information about your health and treatment history, which will help researchers gather important insights into the management of this disease in Brazil.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Male and female;
• • Above 18 years old;
• • Hepatocellular carcinoma diagnosis (confirmed by biopsy or imaging);
• Exclusion Criteria:
• • Fibrollamelar carcinoma, hepatoblastoma, intrahepatic cholangiocarcinoma, neuroendocrine tumors or other less common types of liver tumors;
• • Patients with incomplete staging data;
• • Patients with only 1 visit to the participating site healthcare service, with loss to follow-up prior to the second visit to the participating site healthcare service;
• • Previous treatment for hepatocellular carcinoma in another institution;
• • Treatment with investigational drugs in a clinical trial.